carman research
Post on 08-Jul-2015
1.960 Views
Preview:
TRANSCRIPT
John S. Carman, M.D.Medical Director and Founder of Carman ResearchClinical research for over 38 yearsClinical trial investigator for over 300 clinical trialsBoard certified in psychiatryWell published with previous NIMH and academic experience (University of Alabama)
Nathan Andrew Shapira, M.D., Ph.D.Clinical research for over 12 yearsBoard certified in psychiatry; Ph.D. in neuropathologyWell published with previous industry (SolvayPharmaceuticals and Tikvah Therapeutics) and academic experience (University of Florida)
Experienced Physicians
Edwinia Paden-JohnsonMedical Records CoordinatorWith Carman Research for 26 years
Casey ChaconaSenior Research CoordinatorWith Carman Research for 10 years
Becky Empric and Robin SwinksResearch CoordinatorsWith Carman Research for 7 and 3 years, respectively
Marc McLaughlin and Lori JohnsonOffice Administration and RecruitmentWith Carman Research for 3 years
Dedicated and Stable Team
Broad ExperienceTherapeutic Area Number of Studies (by 2009)Major Depressive Disorder 139 (including 4 TRD)
Schizophrenia/Schizoaffective Disorder 44
Generalized Anxiety Disorder 37
Bipolar Disorder 27 (Mania); 15 (Dep); 4 (Proph)
Alzheimer’s Disorder 11
Panic Disorder 6
Insomnia 5
Social Anxiety Disorder 3
Obsessive-Compulsive Disorder 3
Adult Attention Deficit Disorder 3
Chronic Pain and Fibromyalgia 3
Obesity 1
Clinical Trial Phase Experience
Phase of Development Number (by 2009)
Phase Ib/IIa 10
Phase II 112
Phase III 140
Phase IV 39
Excellent EnrollmentIndication Screened Randomized
Major Depressive Disorder 35 30
Major Depressive Disorder 19 15
Major Depressive Disorder 22 16
Major Depressive Disorder 36 25
Major Depressive Disorder (ext) 15 10
Major Depressive Disorder 56 36
Generalized Anxiety Disorder 12 11
Generalized Anxiety Disorder 22 21
Generalized Anxiety Disorder 13 12
Generalized Anxiety Disorder 26 22
Bipolar Disorder, Depression 14 12
Overall for 2008-2009 (18 months) 270 210 (78%)
Excellent RetentionIndication Randomized Completed
(> 8 weeks)Major Depressive Disorder 30 25Major Depressive Disorder 15 12Major Depressive Disorder 16 9Major Depressive Disorder 25 17Major Depressive Disorder (ext) 10 6Major Depressive Disorder 36 35Generalized Anxiety Disorder 11 9Generalized Anxiety Disorder 21 18Generalized Anxiety Disorder 8 7Generalized Anxiety Disorder 22 18Bipolar Disorder, Depression 12 9Overall for 2008-2009 (18 months) 210 165 (80%)
Physicians integrally involved in every visit andadminister rating scales
Very low rate of rater switching during study
Electronic data capture entered efficiently
Low placebo response rates:24% for Major Depressive Disorder (5 studies)30% for Generalized Anxiety Disorder (3 studies)
High compliance:In a recent phase II GAD trial with pharmacokineticLevels, our subjects demonstrated the highest
Quality Data
For studies over the past 4 years, with greaterthan 10 per arm and code breaks available
Percent confirmed compliance with studymedication.
In its 28 years of existence in Northwest Atlanta,Carman Research has conducted clinical studiesfor more than 60 sponsoring pharmaceutical companies. Carman Research has been involved inpivotal studies leading to approval and/or expansionof indications for 23 psychoactive compounds nowon the market, for over 30 different formulationsor indications:
Abilify Geodon SaphrisAricept Invega Seroquel (IR and XR)Celexa Lexapro Wellbutrin (IR,SR and XL)Depakote Namenda Xanax XRDesyrel (IR and Paxil (IR and CR) Zoloft
Contramid) Pristiq ZyprexaEffexor (IR and XR) ProzacEmsam RemeronExelon Risperdal
Proven Results
top related